EP Patent

EP4005559B1 — Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof

Assigned to Vertex Pharmaceuticals Inc · Expires 2025-02-26 · 1y expired

What this patent protects

Patent listed against Kalydeco.

Drugs covered by this patent

Patent Metadata

Patent number
EP4005559B1
Jurisdiction
EP
Classification
—
Expires
2025-02-26
Drug substance claim
No
Drug product claim
No
Assignee
Vertex Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.